Research Briefing
| Nov 26, 2024
Weight-loss drugs will generate economic gains for the US
We estimate that the weight-loss drug industry will be worth $80bn-140bn annually by 2030, thanks to rising rates of obesity and other weight-related health conditions. Around 40mn Americans will likely use a GLP-1 inhibitor, with most being middle- and high-income earners.
What you will learn:
- Weight-loss drug coverage under Medicare and Medicaid will add to the fiscal deficit in the near term, but some of this will be recovered in the long run as a healthier population increases labor force participation and worker productivity. Although, the reelection of former President Donald Trump adds uncertainty to our outlook for the fiscal impact of weight-loss drugs.
- The weight-loss drug industry will contribute to job growth thanks to the creation of new pharmaceutical manufacturing plants. We estimate a creation of 250,000-500,000 new jobs, but there will likely be some jobs lost to decreased spending at restaurants and bars.

Tags:
Related Services

Service
US Forecasting Service
Access to short- and long-term analysis, scenarios and forecasts for the US economy.
Find Out More

Service
Macro and Regulatory Scenarios
Our models, forecasts, and datasets can be customised to fit the unique needs of your organisation.
Find Out More